Search results for "Antiemetics"

showing 10 items of 14 documents

Is ‘anxiety sensitivity’ predictive of postoperative nausea and vomiting?

2019

BACKGROUND Postoperative nausea and vomiting (PONV) is an extremely distressing side effect for patients. Despite PONV prophylaxis guided by well established scoring systems, the incidence of PONV is still high. OBJECTIVE The aim of the current study was to investigate the predictive value of anxiety sensitivity as an additional independent risk factor for PONV in patients with an increased risk of PONV. DESIGN A noninterventional, observational study. SETTING A tertiary care university hospital. PATIENTS Patients with an increased risk of PONV (i.e. female, nonsmoking) undergoing elective surgery (general, gynaecological, urological, musculoskeletal or neurosurgical) under general anaesthe…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentAnesthesia GeneralAnxietyRisk AssessmentPredictive Value of TestsRisk FactorsInternal medicineHumansMedicineGeneral anaesthesiaProspective StudiesRisk factorElective surgeryAgedPsychological Testsbusiness.industryIncidenceAge FactorsOdds ratioMiddle AgedPrognosisAnesthesiology and Pain MedicineElective Surgical ProceduresPostoperative Nausea and VomitingAnxiety sensitivityAntiemeticsFeasibility StudiesFemaleObservational studymedicine.symptombusinessPostoperative nausea and vomitingEuropean Journal of Anaesthesiology
researchProduct

Comparison of Ondansetron versus Clonidine efficacy for prevention of postoperative pain, nausea and vomiting after orthognathic surgeries : a triple…

2018

Background The aim of this randomized controlled triple blind trial was to compare the efficacy of clonidine with dexamethasone versus ondansetron with dexamethasone for postoperative pain, nausea and vomiting prevention in orthognathic surgery patients. Material and Methods In this clinical trial study, 30 consecutive patients with skeletal class III deformities were candidates for orthognathic surgery in Qaem hospital, Mashhad University of medical sciences, Mashhad, Iran from March to November 2017. These subjects were randomly assigned to two equal number groups, ondansetron or clonidine. Patients received either oral ondansetron 8mg or oral clonidine 150μg as premedication, 1 hour befo…

AdultMaleAdolescentNauseamedicine.medical_treatmentOrthognathic surgeryClonidinelaw.inventionOndansetron03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind Method030202 anesthesiologylawmedicineHumansGeneral DentistryDexamethasoneAnalgesicsPain Postoperativebusiness.industryOrthognathic Surgical ProceduresResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]OndansetronClonidineTreatment OutcomeOtorhinolaryngologyAnesthesiaPostoperative Nausea and VomitingUNESCO::CIENCIAS MÉDICASVomitingAntiemeticsSurgeryPremedicationFemalemedicine.symptomOral Surgerybusinessmedicine.drug
researchProduct

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting in…

1995

Background. A single-institution, randomized open trial was prospectively performed to compare orally administered granisetron with or without intramuscularly administered methylprednisolone to metoclopramide plus methylprednisolone in the prevention of delayed nausea and vomiting induced by cisplatin-based chemotherapy. The effects of antiemetic treatments were evaluated from days 2 to 5 of the first cycle after cisplatin administration among patients who had never before received chemotherapy. Methods. All patients were treated with chemotherapeutic regimens containing cisplatin greater than or equal to 80 mg/m 2 and received antiemetic therapy with granisetron 3 mg intravenously for the …

AdultMaleCancer ResearchMetoclopramideNauseamedicine.drug_classMetoclopramideVomitingmedicine.medical_treatmentAdministration OralGranisetronMethylprednisoloneGranisetronNeoplasmsmedicineAntiemeticHumansProspective StudiesAgedChemotherapybusiness.industryNauseaMiddle AgedOncologyMethylprednisoloneAnesthesiaVomitingCorticosteroidAntiemeticsDrug Therapy CombinationFemalemedicine.symptomCisplatinbusinessmedicine.drugCancer
researchProduct

Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I–II study

2003

Our objective was to identify a new active three-drug combination regimen consisting of paclitaxel (PTX), epirubicin (EPI) and cisplatin as first-line line chemotherapy for advanced ovarian carcinoma. A phase I study was carried out to evaluate the dose-limiting toxicity (DLT) and the maximally tolerated dose (MTD) of PXT and EPI in combination with a fixed dose of cisplatin every 4 weeks. Side-effects were recorded according to the NCI Common Toxicity Criteria. Patients were treated in cohorts of three with fixed-dose cisplatin 80 mg/m 2 and EPI 80 → 100 mg/ m 2 and PXT 100 → 160 mg/m 2 until DLT was reached. Once MTD was identified, a single-step phase II study was therefore carried out t…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPaclitaxelmedicine.medical_treatmentUrologyPhases of clinical researchAntineoplastic AgentsPharmacologyAntineoplastic Combined Chemotherapy ProtocolsMucositisHumansMedicinePharmacology (medical)AgedEpirubicinNeoplasm StagingOvarian NeoplasmsPharmacologyCisplatinChemotherapyAntibiotics AntineoplasticDose-Response Relationship Drugbusiness.industryCarcinomaMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicSurvival AnalysisRegimenOncologyToxicityAntiemeticsFemaleCisplatinbusinessFebrile neutropeniamedicine.drugEpirubicinAnti-Cancer Drugs
researchProduct

Pattern of symptoms and symptomatic treatment in adults and the aged population: a retrospective analysis of advanced cancer patients followed at hom…

2016

Context Data regarding symptom burden and symptomatic drugs in palliative population in different classes of age are lacking. Objective The aim of this retrospective study was to assess the symptom burden, and the profile of symptomatic drugs in the last four weeks of life in adults and older cancer patients followed at home. Methods Charts of 412 patients were retrospectively analyzed by using a backward analysis. Patients were divided into three groups: adults (<65 years, A), old (65-74 years, O1), very old (75-84 years, O2), and the oldest (≥85 years, O3). Results At -4W Karnofsky status was significantly lower for older people (p = 0.03). No significant effect of age on the vector of sy…

AdultMalePediatricsmedicine.medical_specialtyPalliative careNauseaPopulationSymptomatic treatmentPainHome care03 medical and health sciences0302 clinical medicineElderlyAdvanced cancerNeoplasmsRetrospective analysisOld patientsMedicineHumans030212 general & internal medicineAdvanced cancer; Drugs; Elderly; Home care; Old patients; Palliative care; Symptoms; Medicine (all)Karnofsky Performance StatuseducationAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryMedicine (all)Anti-Inflammatory Agents Non-SteroidalAge FactorsCancerDrugsRetrospective cohort studyNauseaGeneral MedicineMiddle Agedmedicine.diseaseAdvanced cancerHome Care ServicesAnalgesics Opioid030220 oncology & carcinogenesisSymptomsPalliative careAntiemeticsFemalemedicine.symptombusinessCurrent medical research and opinion
researchProduct

Aggressive Pharmacological Treatment for Reversing Malignant Bowel Obstruction

2004

Early and intensive pharmacological treatment not only may reduce gastrointestinal symptoms but also reverse malignant bowel obstruction. Fifteen consecutive advanced cancer patients with inoperable bowel obstruction received a combination of drugs including metoclopramide, octreotide, dexamethasone and an initial bolus of amidotrizoato. Recovery of intestinal transit was reported within 1-5 days in fourteen patients, who continued this treatment without presenting symptoms of bowel obstruction until death. This case series establishes that the combination of propulsive and antisecretive agents can act synergistically to allow a fast recovery of bowel transit without inducing unpleasant col…

AdultMalemedicine.medical_specialtyMetoclopramidemedicine.drug_classOctreotideGastroenterologyBolus (medicine)Gastrointestinal AgentsInternal medicineEdemamedicineHumansGeneral NursingDexamethasoneAgedPelvic NeoplasmsTerminal Carebusiness.industrydigestive oral and skin physiologyPalliative CareFecal impactionDrug SynergismRecovery of FunctionMiddle Agedmedicine.diseasedigestive system diseasesBowel obstructionDrug CombinationsAnesthesiology and Pain MedicineTreatment OutcomeAnesthesiaAbdominal NeoplasmsCorticosteroidAntiemeticsFemaleNeurology (clinical)medicine.symptombusinessIntestinal Obstructionmedicine.drug
researchProduct

Metoclopramide and diphenhydramine in the treatment of hyperemesis gravidarum: effectiveness and predictors of rehospitalisation.

2007

Abstract Objectives Hyperemesis gravidarum (HG) is the second most common reason for hospitalisation during pregnancy. Since 2002, a new HG treatment protocol consisting of metoclopramide plus diphenhydramine was put in place at CHU Sainte-Justine, affiliated to University of Montreal, Quebec, Canada. The objectives of this study were to evaluate the effectiveness of this new HG protocol regarding length of hospitalisation for HG, rate of rehospitalisation, evolution of nausea and vomiting symptoms, and rate of adverse events. Study design A retrospective cohort study was conducted from 2002 to 2006 on the population of pregnant women diagnosed with HG, and treated at CHU Sainte-Justine wit…

AdultMetoclopramideAdolescentNauseamedicine.drug_classMetoclopramidePopulationPatient ReadmissionCohort StudiesHyperemesis gravidarumYoung AdultSex FactorsPregnancyHyperemesis GravidarumMorning sicknessmedicineAntiemeticHumanseducationRetrospective Studieseducation.field_of_studybusiness.industryDiphenhydraminePregnancy OutcomeObstetrics and GynecologyLength of Staymedicine.diseaseDiphenhydramineTreatment OutcomeReproductive MedicineAnesthesiaAntiemeticsDrug Therapy CombinationFemalemedicine.symptombusinessDroperidolmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Comparing metoclopramide electrotransport kinetics in vitro and in vivo.

2010

The purpose of this work was to investigate the transdermal iontophoretic delivery of metoclopramide and to determine (i) the dependence of electrotransport on current density and drug concentration, (ii) the relative contributions of electromigration and electroosmosis and (iii) the feasibility of administering therapeutic amounts of drug, using a drug-sparing iontophoretic configuration. Iontophoretic delivery of metoclopramide (MCL) across dermatomed porcine ear skin was investigated in vitro as a function of concentration (10, 20, 40, 80 and 100mM) and current density (0.1, 0.2 and 0.3mAcm(-2)) using vertical flow-through diffusion cells. In vivo studies were performed in Wistar rats (4…

DrugMaleMetoclopramideMetoclopramideSwinemedia_common.quotation_subjectPharmaceutical SciencePharmacologyPharmaceutical formulationIn Vitro TechniquesPharmacokineticsIn vivomedicineAnimalsRats WistarAntiemetics/pharmacokineticsMetoclopramide/pharmacokineticsmedia_commonTransdermalddc:615IontophoresisChemistryIn vitroRatsAntiemeticsmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients

2019

Purpose: Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK 1 receptor antagonist (NK 1 -RA), a 5-HT 3 receptor antagonist (5HT 3 -RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK 1 -RA, netupitant, and second-generation 5HT 3 -RA, palonosetron. So far, no data has been published in literature about the efficacy of a s…

MaleOncologyQuinuclidinesMultiple-dayPyridinesmedicine.medical_treatmentCINVPilot ProjectsDexamethasonechemistry.chemical_compound0302 clinical medicineNeurokinin-1 Receptor AntagonistsClinical endpointSerotonin 5-HT3 Receptor AntagonistsProspective Studies030212 general & internal medicineAged 80 and overSoft tissue sarcomaPalonosetronNauseaSarcomaMiddle AgedReceptors Neurokinin-1PalonosetronOncology030220 oncology & carcinogenesisVomitingFemaleOriginal Articlemedicine.symptommedicine.drugAdultmedicine.medical_specialtyVomitingmedicine.drug_classNauseaAntineoplastic Agents03 medical and health sciencesInternal medicinemedicineHumansAntiemeticNetupitantAuthor CorrectionAgedChemotherapybusiness.industryIsoquinolinesmedicine.diseasechemistryNetupitantAntiemeticsbusinessSupportive Care in Cancer
researchProduct

NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri eve…

2021

OBJECTIVE: The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects. Chemotherapy-induced nausea and vomiting (CINV) are amongst the most troublesome side effects that impair patients’ adherence to treatments and their quality of life (QoL). NEPA (Akynzeo®), is an oral fixed-dose combination of netupitant [a neurokinin-1 receptor antagonist (NK1RA), 300 mg] and palonosetron [(5-hydroxytryptamine (serotonin or 5HT) type3 receptor antagonist (5HT3RA), 0.5 mg] which has been shown to be effective in preventing CINV. PATIENTS AND METHODS: This prospective study started before…

MalePyridinesVomitingCINVLeucovorinCOVID-19NauseaMiddle AgedIrinotecanColorectal cancerBevacizumabOxaliplatinPalonosetronNetupitantAntineoplastic Combined Chemotherapy ProtocolsAntiemeticsHumansEmetogenic chemotherapyFemaleFluorouracilProspective StudiesColorectal NeoplasmsPandemicsAdvanced pancreatic cancerAgedEuropean review for medical and pharmacological sciences
researchProduct